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The increasing demand for liver transplantation and the decline in donor organs has 
highlighted the need for alternative novel therapies to prevent chronic active hepatitis, 
which eventually leads to liver cirrhosis and liver cancer. Liver histology of chronic hepa-
titis is composed of both effector and regulatory lymphocytes. The human liver contains 
different subsets of effector lymphocytes that are kept in check by a subpopulation 
of T  cells known as Regulatory T cells (Treg). The balance of effector and regulatory 
lymphocytes generally determines the outcome of hepatic inflammation: resolution, ful-
minant hepatitis, or chronic active hepatitis. Thus, maintaining and adjusting this balance 
is crucial in immunological manipulation of liver diseases. One of the options to restore 
this balance is to enrich Treg in the liver disease patients. Advances in the knowledge of 
Treg biology and development of clinical grade isolation reagents, cell sorting equipment, 
and good manufacturing practice facilities have paved the way to apply Treg cells as a 
potential therapy to restore peripheral self-tolerance in autoimmune liver diseases (AILD), 
chronic rejection, and posttransplantation. Past and on-going studies have applied Treg 
in type-1 diabetes mellitus, systemic lupus erythematosus, graft versus host diseases, 
and solid organ transplantations. There have not been any new therapies for the AILD 
for more than three decades; thus, the clinical potential for the application of autologous 
Treg cell therapy to treat autoimmune liver disease is an attractive and novel option. 
However, it is fundamental to understand the deep immunology, genetic profiles, biology, 
homing behavior, and microenvironment of Treg before applying the cells to the patients.
Keywords: regulatory T cells, microenvironment, metabolites, microbes
Regulatory T cells (Treg) are critical regulators of immune tolerance (1). Regulatory activity among 
the CD25+ subclass of CD4+ T cells was first discovered in 1995 by Sakaguchi and colleagues via 
adoptive transfer studies. Depleting the CD25+CD4+ T cells from a T cell inoculum increased the 
rate at which graft versus host disease (GVHD) and features of autoimmune diseases developed 
in the recipient strain (2). The immunosuppressive potential of these cells was solidified in the 
result that replacement of the CD25+ fraction of CD4+ T cells could limit autoimmune disease 
induction (2, 3). CD4+CD25+ T cells constitute 5–10% of peripheral CD4 T cells in the blood, 
and they play a crucial role in maintaining immunologic self-tolerance by actively suppressing 
self-reactive lymphocytes (2). Treg development is controlled by FoxP3, which encodes the tran-
scription factor that is genetically defective in an autoimmune and inflammatory syndrome in 
humans and mice (4, 5). IL-7 receptor, CD127 expression inversely correlates with FoxP3 and 
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suppressive function of CD4+ Treg (6, 7); thus, Treg are currently 
defined as a subset of CD4 lymphocytes with the surface marker 
profile CD4+CD25+CD127low and which express the intracellular 
transcription factor FoxP3. Treg are classified into two simple 
and broad categories; thymic-derived Treg (previously known 
as naturally occurring Treg) and peripheral Treg (previously 
labeled as adaptive Treg) (8).
PROFiLe OF ReGULATORY T CeLLS 
iN LiveR DiSeASeS
The majority of chronic active hepatitis is immune-mediated 
liver injury (9). Many investigators have reported Treg fre-
quency variation in the peripheral blood in acute liver injury, 
chronic liver diseases, and liver cancer, but there are limited 
data on intrahepatic Treg. Reduction in CD4+CD25highCD127low 
Treg frequency has been described in patients with alcoholic 
hepatitis (10). Progression from non-alcoholic fatty liver to 
non-alcoholic steatohepatitis is characterized by a higher 
frequency of Th17 cells in the liver and an increased ratio of 
Th17/resting CD4+CD45RA+CD25high Treg in peripheral blood 
(11). We, and others, have reported that there is an increase 
in Treg frequency in parallel with effector immune cells in 
autoimmune liver diseases (AILD) (12–15). Treg also appear 
to play a role in the immunopathogenesis of primary biliary 
cholangitis (PBC) (16). Indeed, reduced FoxP3 expression in 
Treg has been described in the portal tracts of patients with 
PBC (17). Our group has previously reported the existence of a 
gut–liver link with the aberrant homing of mucosal T cells from 
the gut to the liver and extra-intestinal manifestations being 
seen in inflammatory bowel disease (18–20). Biliary epithelial 
inflammation has also been associated with the accumulation of 
CCR10-expressing Treg around the bile ducts in the liver (21).
In the setting of acute liver injury, such as acute viral hepatitis 
A, the size of the Treg pool was contracted due to Treg apop-
tosis via a Fas-mediated mechanism (22). Hepatitis B (HBV) 
pathogenesis is immunologically mediated and increased 
frequencies of CD4+ CD25highCD45RO+ Treg and cytotoxic 
T-lymphocyte-associated antigen 4 (CTLA-4) cells were noted 
in the peripheral blood of patients compared with controls and 
in patients who had recovered from a previous episode of HBV 
infection (23, 24). However, in HBV-related acute or chronic 
liver failure, while there was a reduction noted in CD4+ T cells, 
Treg numbers remained unchanged (25). In addition, serial 
biopsies from patients chronically infected with hepatitis C virus, 
taken during and after antiviral therapy, suggested that intrahe-
patic CD4+CD25highFOXP3+ Treg frequencies were increased 
upon interferon and ribavirin therapy in about half of patients, 
indicating stronger regulation of intrahepatic immunity by Treg 
during antiviral therapy (26). It is generally accepted that Treg 
are not beneficial in the setting of liver cancer as an increased 
Treg frequency correlates with CD8+ T cell impairment and poor 
survival of patients (27). All this body of evidence suggests that 
Treg play a major role in different types of liver diseases.
The Treg population has been classified as CD25+CD45RA+ 
FOXP3low resting, CD25++CD45RAnegFOXP3high activated, sup-
pressive Treg and CD25+CD45RAnegFOXP3low cytokine-secreting 
non-suppressive Treg (28) (Figure  1). We recently described 
intrahepatic Treg as predominantly effector memory lymphocytes 
with PD1low, CD69high phenotype (15) and expressing both hepatic 
homing CXCR3 and biliary tropic CCR6 chemokine receptors 
(14) (Figure 1).
SUPPReSSive MeCHANiSMS 
OF ReGULATORY T CeLLS
Regulatory T cells are potent mediators of self-tolerance in the 
periphery and function via multiple mechanisms to achieve 
immune modulation. Treg exert their functions by (i) inhibiting 
the function or maturation of antigen-presenting cells (APCs), 
(ii) destroying target cells by inducing apoptosis, (iii) causing 
metabolic disruption via the adenosine pathway, and (iv) by 
secreting immunosuppressive cytokines, transforming growth 
factor beta (TGF-β), and IL-10 or competitive consumption of 
survival cytokines in particular IL-2 (Figure 2).
T-lymphocyte-associated antigen 4 (CTLA-4) protein expres-
sion on Treg plays an important role in the suppressor function 
of Treg (29). In particular, deficiency of CTLA-4 in Treg impairs 
their suppressive function to result in fatal T cell-mediated auto-
immune disease. CTLA-4 via the process of trans-endocytosis 
depletes its two ligands, CD80 and CD86 from dendritic cells 
(DCs), thereby removing their availability to act as costimula-
tory ligands through CD28 (30) (Figure 2). In vitro studies have 
also identified that CTLA-4 can additionally suppress T-cell 
proliferation via upregulation of several essential amino acid 
consuming enzymes, including indolamine 2,3-dioxygenase, 
histidine ammonia lyase, nitric oxide synthase 2, and l-threonine 
3-dehydrogenase in APC through binding CD80 on the APC cell 
surface (31). IDO-positive DCs represent a regulatory subset 
of APCs in humans (32) (Figure 2). Regulation of tryptophan 
metabolism by indolamine 2,3-dioxygenase (IDO) in DCs is a 
highly versatile modulator of immunity. IDO converts trypto-
phan to kynurenine, which inhibits the proliferation of effector 
T cells (33) (Figure 2) but promotes FoxP3 induction in a mecha-
nism involving reduced PI3K/mTOR signaling (31). Importantly, 
we have shown that human intrahepatic Treg reside close to DCs 
and effector T cells to exert their suppressive function in the 
areas of chronic hepatitis, either in the lobules or in the areas of 
interface hepatitis (34).
TGF-β1, an immunosuppressive cytokine, supports the 
maintenance of FoxP3 expression, regulatory function, and 
homeostasis in peripheral Treg (35). It is also a crucial cytokine, 
which dictates the development of a Treg versus Th17 lineage 
(36) and limits T effector proliferation via induction of essential 
amino acid catabolizing enzymes in APCs. IL-10 released by Treg 
also promotes essential amino acid depletion via upregulation of 
certain catabolizing enzymes in APCs (31). The liver is enriched 
with TGF-β1 (37, 38) (Figure  3). Recently, CD103+ intestinal 
DCs have been shown to promote a tolerogenic environment 
via integrin αvβ8-mediated activation of TGF-β (39), and DCs 
lacking αvβ8 fail to induce Treg (40).
Treg could also suppress or kill responder T  cells after cell 
to cell contact in a perforin-dependent and independent man-
ner by granzymes A and B (41, 42). Treg can also inhibit T cell 
FiGURe 1 | The anatomical location of Treg cell subsets and their phenotypic markers in humans. (A) Thymus-derived Treg (tTreg) cells are generated in 
the thymus from naive CD4+ T cells in combination with several stimulating factors. They express transcription factors and surface markers specific to all Treg 
subsets in addition to those specifically upregulated only in tTreg, such as PD-1, Helios, and Nrp-1. (B) Peripheral blood flow contains all circulating Treg subsets, 
including three subpopulations that may be defined by their expression of CD45Ra and FoxP3. (C) In tissues such as the liver, naive CD4+ cells may differentiate into 
peripherally derived Treg cells (pTreg) in response to stimulating factors. These cells express many of the same transcription factors and surface markers as tTreg 
with notable differences, such as reduced Helios, Nrp1, CD73, and PD-1 expression.
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proliferation by inducing pericellular adenosine from extracel-
lular nucleotides (43, 44), which is catalyzed by ectoenzymes, 
CD39, and CD73 expressed on Treg (45, 46). The coordinated 
expression of CD39/CD73 on Treg and the adenosine A2A 
receptor on activated T effector cells generates immunosup-
pressive loops, implementing the inhibitory function of Treg 
cells (43, 47) (Figure 2). We reported previously that there is an 
increase in the frequency of intrahepatic Treg in inflamed human 
livers (34) in parallel with total CD4 T cells, and they had high 
expression of their functional markers such as CTLA-4, CD39, 
and also secreted IL-10.
IL-2 is a potent inducer of T-cell proliferation and T-helper cell 
differentiation and is necessary for the survival and function of 
memory T cells. It is also important for the development, survival, 
and function of Treg (45, 48, 49). Treg have higher expression 
of the high-affinity IL-2 receptor subunit, CD25, than effector 
T  cells; thus, Treg can suppress effector cell proliferation and 
differentiation by competitive consumption of IL-2 when located 
in close proximity (50). However, the functional capacity of intra-
hepatic Treg is reduced in the IL-2-deficient inflamed hepatic 
microenvironment (15). We demonstrated that the main source 
of intrahepatic IL-2 is activated T effector cells, and this cytokine 
FiGURe 2 | Treg mechanisms of action. (a) CTLA-4/CD80/CD86 trans-endocytosis. (ai) CTLA-4 on the surface of Treg binds to CD80/CD86 on the dendritic cell 
surface. (aii) CTLA-4 and CD80/CD86 are brought into the Treg via endocytosis. (aiii) CD80/CD86 fuses with lysosomes to be broken down, while CTLA-4 is 
recycled to the cell membrane. (b) IDO-mediated tryptophan deprivation. Binding of CTLA-4 and CD80/CD86 stimulates induction of the enzyme Indoleamine 2, 
3-dioxygenase (IDO) in CD123+CCR6+ dendritic cells, which catalyzes the conversion of Tryptophan to N′-Formylkynurenine. The resulting Tryptophan depletion 
leads to CD4+ cell death. (c) Conversion of ATP to adenosine via CD39/CD73. CD39 and CD73 expressed on the Treg cell surface convert ATP/ADP released from 
respiring hypoxic cells into adenosine, which binds to receptors on activated T effector (Teff) with an inhibitory effect. Depletion of ATP also suppresses Teff 
proliferation. (d) Cytokine release. TGF-β and IL-10 released by Treg inhibit Teff cell proliferation and activation. (e) Induction of apoptosis. Release of Granzyme A, 
Granzyme B, and perforin by Treg leads to apoptosis of Teff. (f) IL-2 deprivation. Deprivation of IL-2 from CD4+ T cells by CD25 on the Treg surface leads to cell 
death.
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is crucial for Stat5 signaling in Treg (15). IL-2 is also required 
for the homeostatic maintenance of Treg. Taken together, such 
low intrahepatic IL-2, which appears reduced further in disease, 
might contribute to a lack of Treg-conferred protection and the 
progression of immune-mediated liver diseases. Indeed, autoim-
mune diseases can be induced by IL-2 neutralization or defective 
IL-2 production (51, 52).
Thus, Treg exert suppression in multiple pathways. The 
mechanism is dependent on the specific tissue and its microen-
vironment (Figure 2).
HePATiC MiCROeNviRONMeNT AND 
ReGULATORY T CeLLS
Intrahepatic Treg are residing in a microenvironment, which 
is deprived of oxygen and enriched with microbes, metabolic 
products; inflammatory cytokines, and hormones, which all play 
a role in Treg differentiation and function (Figure 3). The liver 
is enriched with fat-soluble vitamins. All-Trans retinoic acid 
(ATRA), a metabolite of vitamin A, is enriched in Ito cells (stel-
late cells) and plays a pivotal role in maintaining the stability and 
function of Treg in the inflammatory milieu (53, 54). Retinoic 
acid can also directly promote TGF-β-mediated conversion of 
naive T cells to cells of FoxP3+ Treg phenotype (55, 56). In addi-
tion, retinoic acid can prime human DCs to induce gut homing, 
IL-10-producing Treg (57) (Figure 3).
The active form of vitamin D, 1,25-dihydroxyvitamin D3 
and IL-2 synergistically combine to inhibit T cell production 
of inflammatory cytokines and promote development of Treg 
expressing CTLA-4 and FoxP3 (58) (Figure  3). One recent 
report showed that short-chain fatty acids (SCFA) from gut 
microbiota-derived bacterial fermentation products regulate the 
FiGURe 3 | The influence of cytokines, hypoxia, dietary metabolites, microbiota, and hormones on the generation of peripherally derived regulatory 
T cells (pTreg) in the liver. (a) TGF-β and IL-2 signal to promote the differentiation of naive CD4+ T cells, while TNF-α impairs differentiation. Leptin released by 
adipocytes impairs the proliferation of pTreg cells. (b) Cytokines released during liver inflammation can lead to hypoxic conditions, which stabilizes the transcription 
factors hypoxia-inducible factor 1α and 2α (HIF-1α/HIF-2α) in naive CD4+ T cells. These factors stimulate FoxP3 expression and a move toward a pTreg phenotype. 
(c) Dietary vitamin D3 brought to the liver via the portal vein is metabolized into its active form 1,25 (OH2) VD3 or calcitriol, which enhances CTLA-4 expression and 
antagonizes Th17 cytokines in all T cells, including pTreg, via the vitamin D receptor (VDR). Dietary vitamin A is converted to all-trans retinoic acid (ATRA) by CD103+ 
dendritic cells in the liver sinusoid, which in combination with ATRA released by stellate cells and IL-2, stabilizes FoxP3 and the pTreg phenotype. (d) TGF-β in 
combination with IL-2 or IL-6 will differentiate naive CD4+ T cells into pTreg or Th17 cells, respectively. (e) Propionate is a short-chain fatty acid that is metabolized by 
gut microbes and binds to GPR43 receptor to stabilize the pTreg phenotype. The bacteria component polysaccharide A (PSA) binds to TLR-2 on dendritic cells, 
which increases pTreg differentiation. The influence of these products in the liver is unknown.
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size and function of the colonic Treg pool and protect against 
colitis, suggesting that abundant microbial metabolites underlie 
adaptive immune microbiota coadaptation and promote colonic 
homeostasis (59). We have also reported that the inflamed liver 
microenvironment is enriched with pro-inflammatory cytokines 
IL-1, IL-12, IL-6, IL-8, and TNFα, but deprived of the Treg 
survival cytokine IL-2 (15). Nonetheless, although they present 
a somewhat reduced regulatory capacity, intrahepatic Treg still 
possess an intact functional capacity and maintain their lineage 
for a short time in culture conditions that mimic the intrahepatic 
environment (15).
There is a shift in metabolic supply-and-demand ratios dur-
ing inflammation. Tissue hypoxia within inflammatory lesions 
dictates an anti-inflammatory program by driving expression 
of hypoxia-inducible factor (HIF)-1α that acts to increase the 
frequency and suppressive properties of thymic Treg (60, 61). 
6Jeffery et al. Treg Therapy in Liver Diseases
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Indeed, hypoxic Treg were more effective than normoxic cells in 
suppressing the proliferation of effector lymphocytes (61). The 
hepatic microenvironment is a hypoxic atmosphere especially 
around zone 3, where cells are closer to the central vein and most 
distant from the hepatic artery oxygen supply. Thus, while not 
proven, a gradient in Treg potency might be expected through 
the liver.
The liver is continuously exposed to gut microbes and bacterial 
toxins via its portal venous flow. It is clear that the microbiome has 
a strong influence on the immune system. For example, breast-fed 
infants develop robust populations of memory T cells as well as 
T helper 17 (Th17) cells within the memory pool, whereas bottle-
fed infants do not, and this may partly explain the variation in 
human susceptibility to conditions with an immune basis, as well 
as the variable protection against certain infectious diseases (62). 
Oral bacteria administration in mice also promotes Treg and 
alleviates bowel inflammation in a model of immune-mediated 
colitis (63); thus, the microbiome may serve as a target for future 
Treg-based immunotherapies.
ReCRUiTMeNT AND POSiTiONiNG OF 
Treg TO THe iNFLAMeD LiveR
Leukocyte trafficking and positioning within tissues is directed 
by chemokines. Thus, chemokines play critical roles in regulating 
immune responses and inflammation (64, 65). Chemokines can 
be classified into “inflammatory” and “homeostatic/constitutive” 
based on whether they are induced by inflammation or consti-
tutively expressed and involved in homeostatic immune regula-
tion (64). Hepatic Treg express a unique range of chemokine 
receptors, which interact with corresponding chemokines, and 
these receptors are crucial for their homing and positioning in 
the inflammatory liver tissues. Human intrahepatic Treg express 
the chemokine receptor CXCR3 for recruitment across hepatic 
sinusoids, CCR4 for positioning close to hepatic DCs and both 
CXCR3 and CCR6 chemokine receptors for positioning around 
bile ducts (15, 34). This chemokine receptor expression profile 
is essential for Treg to locate at the site of inflammation and to 
interact with other immune cells. CXCR3 deficiency has been 
shown to exacerbate liver disease and abrogates tolerance in 
mouse models of immune-mediated hepatitis (66).
CLiNiCAL APPLiCATiON OF Treg
As has been discussed, Treg play a pivotal role in controlling the 
magnitude of immune responses to provide tolerance to self-
antigens and to limit tissue damage caused by immune activation 
in response to innocuous antigens. Given the contribution of 
aberrant immune control in the progression of disease includ-
ing: (1)  suppressed effector immune response which results 
in unwanted Treg activity in cancer, (2) impaired immune-
regulatory function in autoimmune or inflammatory diseases, 
and (3) the deleterious consequences of life-long immunosup-
pression therapy following organ transplantation, the prospect 
to control disease progression through targeting the regulatory 
cells in settings of cancer, solid organ and hematopoietic cell 
transplantation, transplant rejection, and autoimmune diseases 
has been an attractive option for clinicians over many years.
The cytokine IL-2 is essential for the function and expansion 
of Treg (49). Thus, to improve immune regulation through low-
dose, IL-2 therapy, which targets the Treg selectively in contrast 
to effector, has been tested with positive outcomes in human 
autoimmune-related diseases in Phase I and II settings (67–70).
The establishment over recent years of good manufacturing 
practice (GMP)-compliant reagents and equipment that can 
allow the isolation of cells according to their expression profile of 
certain surface proteins has made it possible to isolate Treg from 
the peripheral circulation as a cell immunotherapy. The concept 
underlying this “Regulatory T cell therapy” is that administering 
a concentrated source of a desired population of Treg can tip the 
balance of the patient’s immune system to enhance its regulatory 
capacity. It builds on the knowledge that a lack of Treg function 
due to mutation of the Treg lineage-defining transcription factor 
FOXP3 leads to the X-linked autoimmune syndrome immune dys-
regulation, polyendocrinopathy, enteropathy X-linked syndrome 
(IPEX) (71), and, upon the seminal observation by Sakaguchi and 
colleagues, that giving CD4+CD25+ Treg could prevent autoim-
mune disease (2). In this section, we discuss developments in the 
field of Treg immunotherapy and its potential to be used to treat 
liver diseases in the future.
GeNeRATiON OF GMP-COMPLiANT 
CLiNiCAL GRADe Treg FOR CeLL 
THeRAPY
To be used therapeutically, a cellular product must be deemed 
GMP-compliant. This has massive implications upon its produc-
tion compared with a basic laboratory reagent as the final product 
and all the reagents and equipment used in its manufacture must 
exceed a standard clinical quality (purity) and sterility. Accordingly, 
all staff involved in its preparation must be highly skilled in aseptic 
procedures and must receive regular re-training. There must be 
a detailed log of the production and characterization of the final 
product. Altogether, this imposes extremely high overheads 
to the production of cellular therapies and with regard to Treg 
cell therapy has further limited the precise phenotypic character 
that can be achieved both for practical and for financial reasons. 
Consequently, the Treg used in trials until now have differed.
To date, we can define three categories of GMP-grade clinical 
Treg: first generation (CD4+CD25+); second generation, bone 
fide Treg (CD4+CD25+CD127low/−), and third generation naive 
Treg (CD4+CD25+CD127low/−CD45Ra+) (Figure  4). There are 
two options to achieve GMP clinical grade Treg, bead-based 
GMP technology and flow sorting technology. While first gen-
eration Treg can be isolated by magnetic bead-based approaches 
alone, such as CD8 and CD19 depletion followed by CD25 
enrichment, there are no GMP bead reagents to deplete CD127-
expressing effectors. Isolation of second and third generation 
Treg that are exclusively CD127low/− depends on the availability 
of a GMP-compatible flow sorting facility. Tyto technology 
(Miltenyi Biotec) now exists that can facilitate the isolation and 
expansion of a highly pure second (CD4+CD25+CD127low/−) and 
FiGURe 4 | The good manufacturing practice-compliant methods for isolation and expansion of Treg for therapeutic application in liver 
transplantation or treatment of autoimmune liver diseases. (a) Peripheral blood mononuclear cells (PBMC) are isolated from the peripheral blood of the 
patient by density gradient centrifugation of the leukapheresis product. (b–d) Different approaches may then be used to isolate polyclonal Treg characterized by 
certain combinations of surface markers. The absolute phenotype of Treg that can be purified depends on the availability of GMP-compliant antibody-coated 
microbeads and/or flow cytometry antibodies as well as a GMP magnetic sorting system and/or GMP flow sorting facility. (b) CD4+CD25+ Treg are isolated by 
microbead depletion of CD8+ T cells and CD19+ B cells followed by microbead positive isolation of CD25high cells. Short incubation at low temperature with 
anti-CD25 microbeads helps recover only those cells expressing CD25 at high levels (CD4+ Treg). (c) Microbead-based enrichment of CD4+ T cells followed by 
flow sorting for CD25high CD127low/− cells allows isolation of the bona fide (second generation) Treg population with greater percentage FoxP3+ Treg than first 
generation Treg. (d) Additional selection based on CD45Ra expression by flow sorting can isolate a Treg population with enhanced propensity to proliferate. (e) The 
isolated Treg are a polyclonal population (blue halo) but the product is insufficient in number for therapeutic efficacy. (e) Treg are, therefore, expanded by culture 
with anti-CD3/anti-CD28-coated expansion beads in the presence of IL-2 to promote proliferation and survival, rapamycin to kill contaminating T effector cells and 
retinoic acid to enhance the Treg phenotype. These polyclonal-expanded autologous Treg may then be infused to the patient. However, donor alloantigen-reactive 
Treg (darTreg) (orange halo) have greater potency in preventing graft rejection following transplantation and can be isolated from the initial polyclonal Treg pool by 
culture with antigen-presenting cells from the donor (f). Similarly, against autoimmune disease, autoantigen-specific Treg are expected to have greater potency 
(green halo). In many cases, the offending autoantigen is not known but isolation of Treg based on markers such as latency-associated peptide (LAP) and 
glycoprotein A repetitions predominant (GARP) might help to generate a population that has enrichment of autoantigen-specific Treg and which following 
non-specific expansion with anti-CD3/anti-CD28-coated microbeads can be returned to the patient to provide stronger regulation of inflammation than a 
polyclonal preparation (g).
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third generation (CD4+CD25+CD127low/−CD45Ra+) GMP Treg 
preparation straight from a leukapheresis product within a closed 
system, reducing the risk of loss of sterility and optimizing the 
purity of the preparation from the start. Moreover, by includ-
ing Rapamycin and Retinoic acid in the culture cocktail during 
subsequent expansion, it is possible to ensure that loss of purity 
through the outgrowth of any contaminating effector T cells is 
not of concern. Rapamycin precludes the expansion of effector 
but not regulatory T cells via differential downstream signaling 
from the IL-2R (72). Furthermore, additional supplementation 
with IL-2 ± retinoic acid can help to support Treg proliferation 
and potentiate the functional phenotype (73), and it is possible to 
measure the demethylation status of the Treg-specific demethyl-
ated region (TSDR) prior to administration of the cell therapy 
product to the patient to verify purity. Although percentage 
demethylation boundaries are not yet rigorously defined, such 
could be implemented during trials to help restrict any adverse 
events based on known lack of purity.
Treg iMMUNOTHeRAPY FOR LiveR 
TRANSPLANTATiON AND AUTOiMMUNe 
LiveR DiSeASeS
To date, GMP Treg therapy has not been reported in the treat-
ment of the liver diseases either in preventing rejection of donor 
organs, preventing GVHD posttransplant, enabling withdrawal 
of immunosuppressants or overcoming any need for them post-
transplant, or in inducing or maintaining states of remission in 
the pre-transplant setting, but evidence from animal studies (2, 3, 
74, 75) and trials of Treg immunotherapy in other human disease 
backgrounds provide sound rationale for the attempted use of 
this therapy in liver medicine in the future. This is particularly 
important in an era when the demand for liver transplants exceeds 
the availability of matched donor livers. Currently, the first clini-
cal trials are underway, investigating the safety and feasibility of 
Treg therapy in renal transplantation (76, 77), and it is likely that 
outcomes of this trial could be applicable to similar solid organs 
such as the liver.
Application of Treg immunotherapy to 
induce Liver Transplantation Tolerance
Successful solid organ transplantation requires the regulation 
of two immune reactions: (i) antigenic activation of the donor 
immune system against the host that if not restrained leads to 
GVHD and (ii) antigenic activation of the host immune system 
toward the graft, which can lead to graft rejection. GVHD is a 
major complication in the setting of bone marrow transplanta-
tion, owing to the preponderance of T cells in bone marrow, 
but in solid organ transplant it is generally of lesser concern. 
Moreover, the tolerogenic nature of the liver and its ability to 
regenerate (78) means that the recipient–donor match in liver 
transplant need be less stringent and the recipient to donor 
immune response is perhaps the area of gravest concern thera-
peutically. This is currently targeted through life-long immu-
nosuppression, but leaves individuals at risk of opportunistic 
infections, diabetes, hypertension, and malignancy (79).
The first human studies of Treg cell therapy explored its 
potential in the regulation of GVHD and tested HLA-matched 
sibling donor-derived expanded CD4+CD25+CD127low/− (second 
generation) Treg to combat the difficulty in treating GVHD, 
following allogeneic bone marrow or stem cell transplantation 
(80, 81). Although, these initial studies had mixed outcomes, they 
provided hope for Treg therapy in GVHD and highlighted the 
possible importance of timing and dose. A more recent Phase 
I dose escalation study of Treg tested the use of partially HLA-
matched donor umbilical cord blood as opposed to peripheral 
blood (82).
Excitingly, Todo and colleagues brought a new concept of 
Treg-based therapy to the table of operational tolerance in living 
donor liver transplantation (83). In this instance, the straightfor-
ward coculture of irradiated donor lymphocytes collected from a 
leukapheresis product with recipient lymphocytes in the presence 
of anti CD80/86 monoclonal antibodies generated a recipient cell 
product that proved enriched with cells of regulatory phenotype. 
In vitro, these cells inhibited the proliferation of recipient cells 
in response to donor cell stimulation in a dose-dependent man-
ner, and, in vivo, the therapy allowed immunosuppressive agents 
to be tapered and completely discontinued within 18  months. 
This is revolutionary in the field as at the time of reporting 7/10 
subjects had had successful weaning and remained drug free for 
up to 33 months. Successful weaning from immunosuppressant 
has previously been described between 3 and 11 years following 
transplant with longer delay giving higher (up to 80%) success 
(84). Only three individuals who were patients with autoimmune 
liver disease did not tolerate the novel therapy well, and, thus, its 
potential in the setting of autoimmune liver disease transplanta-
tion tolerance requires further consideration (83).
Application of Treg Cell Therapy to 
Restore Peripheral immune Tolerance in 
Autoimmune Liver Diseases
Regulatory T cell therapy has not yet been tested in the AILD 
in humans. Since there have been no advances in new therapies 
for these diseases in the last three decades, observations of 
reduction of Treg and/or impairment of Treg function in these 
diseases supports the concept of Treg therapy in AILD (12, 15, 17, 
85). Treg therapy is an attractive option and especially now that 
standard operating procedures (SOPs) and GMP reagents and 
equipment are in place for the automated and safe manufacture 
of patient-specific cell-based therapies. It is also being considered 
as a future therapy for a number of other autoimmune diseases, 
including inflammatory bowel disease and Crohn’s disease (86, 
87), rheumatoid arthritis (88), and systemic lupus erythematosus 
(SLE) (89). Although a lack of regulatory control is clear in these 
diseases, the precise roles of Treg in the pathogenesis of these 
diseases are unclear as studies have been contradictory with 
regard to changes in frequency and impaired functionality, and it 
may be that the lack of control is due to defects in the capacity of 
the antigen-presenting and/or effector cells to be downregulated 
by the regulatory cells.
To date, the seminal pioneering studies in this arena have been 
in type-1 diabetes, an autoimmune disease of the pancreatic beta 
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islet cells wherein destruction of the beta islets by autoreactive 
T cells leads to loss of production of the hormone insulin, which 
is vital to the regulation of blood glucose. The first safety study in 
humans was in 2012 in a pediatric cohort. Ten children were given 
1 or 2 × 107 CD4+CD25+CD127low/−Treg/kg body weight without 
any adverse events. Significant increases in the proportions of 
peripheral Treg were measured after transfer and importantly at 
6 months post treatment. Eight out of the 10 children, receiving 
Treg therapy, were in remission with 2 weaned off from insulin 
therapy completely. This was in comparison to the control cohort, 
all of whom continued to require insulin therapy (90).
Subsequent work by Tang and colleagues has evaluated safety 
in adults, testing escalating doses of CD4+CD25+CD127low/− Treg 
between 5 × 106 and 3.2 × 108 cells. No serious adverse events 
were observed with the dose escalation study, and an improve-
ment in C-peptide level was noted (91). By including [6,6-2H2] 
glucose, which incorporates into the deoxyribose moiety of newly 
synthesized DNA during expansion, the researchers were able to 
non-radioactively label the Treg and follow their persistence in 
the patient following infusion. Excitingly, although only 25% 
of the peak label was retained on cells at 90 days, it could still 
be detected up to 1 year, suggesting maintenance of the infused 
Treg (91). Furthermore, expressions of Treg-defining markers, 
including FoxP3, CD25, and CD127, remained stable in Treg post 
infusion, and there was not a shift toward a T effector cytokine 
profile. Thus, these studies in type-1 autoimmune diabetes pro-
vide good support for attempting Treg immunotherapy to treat 
AILDs, including autoimmune hepatitis (AIH), primary scleros-
ing cholangitis (PSC), and PBC in the future. However, no study 
has yet verified that Treg cells administered actually reach the site 
of disease, establish persistence at the site and maintain a stable 
phenotype overtime. The recent study by Todo and colleagues 
applying Treg in the setting of living donor liver transplant did 
perform liver biopsies at regular intervals during follow up to 
detect the graft inflammation and fibrosis, but no immunology 
study was done on the liver allograft after Treg infusion to inves-
tigate the localization and fate of the infused cells at the tissue 
level (83). To fully understand outcomes of therapeutic efficacy 
in future trials of the therapy, it would be of advantage if these 
questions could be tackled through biopsy and or/novel in vivo 
imaging methods post treatment.
OPTiMiZATiON OF ReGULATORY T CeLL 
THeRAPY FOR APPLiCATiON iN THe 
LiveR DiSeASeS
Taken together, studies using GMP Treg, whether first or second 
generation, appear promising although clearly the optimization 
of factors including dose, timing relative to transplant/disease 
stage, as well as the choice of immunosuppression regimen and 
the frequency of Treg reapplication are important, and it is likely 
that each of these will be dictated by the individual situation (pro-
phylactic pre or posttransplant versus autoimmunity/GVHD/
rejection), the grade of the individual’s disease, and whether the 
patient’s disease is in remission (requiring withdrawal of standard 
medication) or in relapse (requiring settling of active immune 
reactions as well as withdrawal of standard medications). Given 
that Cyclosporine reduces Treg number, immunosuppression 
therapies used together with Treg therapy should be tailored 
to a rapamycin-based regimen along with Tacrolimus, which 
increases Treg survival. Patients with active viral infection and 
previous history of malignancy should be excluded from any Treg 
clinical trial as Treg would have a negative impact on the disease 
process.
It seems likely that isolated cells will have to be expanded in 
order to be of adequate number to be used in therapy. Hence, one 
caveat will, therefore, be the reliable expansion of autologous Treg 
cells for all patients since most studies, to date, have reported a 
few subjects who were enrolled but failed to receive treatment or 
treatment at the intended dose due to an inadequate cell yield.
The question over the preparation of the Treg also remains. 
Until now the Treg tested in clinical trials have been polyclonal 
and, thus, have ability to function through indirect pathways but 
also specifically due to a number within the mix that have donor 
antigen specificity (namely alloantigen-specific Treg). With a 
view to optimize Treg for transplantation therapy, polyclonal 
and alloantigen-specific Treg have been compared. Alloantigen-
specific Treg represent those Treg that are activated by donor-
specific antigens and can be expanded from polyclonal Treg 
populations in mixed lymphocyte reactions with donor APCs. 
By contrast polyclonal Treg are expanded with anti-CD3/anti-
CD28-coated expander beads. Alloantigen-specific T cells can 
be identified and selected for further expansion based on their 
induction of activation markers such as CD69 and CD71. The fact 
that the therapeutic product created by Todo et al. through mixed 
lymphocyte reaction had greater suppressive ability over recipient 
T cells activated by donor as opposed to third-party stimulation 
was clear evidence of underlying allospecific regulatory activity 
having been raised within the expanded culture, and, as such, 
using a system to generate greater donor specificity might be 
advantageous and should allow considerably reduced numbers 
of Treg to be used (83). The value of alloantigen-specific Treg in 
transplantation tolerance was cleverly demonstrated in vivo using 
a humanized mouse model of human skin graft immune rejec-
tion. Allogeneic Treg expanded on myeloid DCs from the skin 
were more effective at limiting dermal and inflammatory pheno-
types of skin rejection by infusions of allogeneic T effector cells 
than polyclonal Treg (74). Various methods have been proposed 
to generate GMP-compliant donor alloantigen reactive Treg 
(darTreg) for therapeutic application. Appropriate alternative 
cell types to incorporate in coculture with recipient CD4+CD25+ 
Treg to drive the expansion of darTreg include donor PBMCs, 
donor monocyte derived DCs, and donor B cells (92) activated 
on 3T3 fibroblasts expressing CD40L (93). A number of cur-
rent phase 1 and phase 2 clinical trials propose the application 
of darTreg as opposed to polyclonal Treg (Table  1). Similarly, 
in autoimmunity, where models of disease propose the likely 
hood of only a defined autoantigen, antigen-specific Treg may 
be the way forward, but this requires knowledge of the offending 
antigen. In the liver diseases, autoantigens for type II AIH (94) 
and PBC (95) are known but for type I AIH and PSC are yet to 
be discovered precluding the benefits of antigen-specific therapy 
at the present time. Nonetheless isolation of Treg expressing 
TABLe 1 | Clinical trials in regulatory T cell therapy in solid organ transplantation or autoimmune diseases that were listed as recruiting in the www.
ClinicalTrials.gov registry at the time of manuscript preparation (accessed 04-05-2016).
Title of study/www.
ClinicalTrials.gov identifier
Sponsor Location of study Start date/end date/
enrollment/phase
Purpose of the study
deLTa: darTregs in liver 
transplantation/NCT02188719
NIAID 1. University of California 
San Francisco, USA
December 2014/
January 2022/24/
phase 1
To evaluate the safety of taking a specific 
combination of immunosuppressant drugs after liver 
transplantation and the safety of receiving one of 
three doses of darTregs while taking this combination 
of immunosuppressant drugs
2. Mayo Clinic 
Minnesota, USA
The ONE study: Infusion of Treg 
in kidney transplant recipients/
NCT02091232; The ONE study is 
a unified approach to evaluating 
cellular immunotherapy in solid 
organ transplantation
Massachusetts 
General Hospital
Collaboration of US 
and EU Centers
May 2014/May  
2018/8/phase 1
To test different types of Treg for safety and the 
promotion of kidney survival
To examine in living donor renal transplant recipients 
the safety and feasibility of administering Treg derived 
from recipient PBMC stimulated with kidney donor 
PBMC in the presence of costimulatory blockade with 
belatacep
ONETreg1: The ONE study UK 
Treg Trial/NCT02129881.
Guy’s and St 
Thomas’ NHS 
Foundation Trust
1. Guy’s Hospital, 
London, UK
April 2014/March 
2017/12/phase 1 
and phase 2
To asses autologous expanded polyclonal Treg as a 
treatment to prevent kidney transplant rejection with 
infusion into the patient 5 days after kidney transplant 
for end-stage renal failure
2. The Oxford Transplant 
Centre, Oxford, UK
DART: darTreg therapy in renal 
transplantation. The ONE study 
US Treg Trial/NCT02244801
University of 
California, San 
Francisco
University of California, 
San Francisco
November 2014/June 
2018/16/phase 1
To evaluate the safety and tolerability of darTreg 
infusion for adult, de novo living donor renal transplant 
recipients
ARTEMIS: darTregs for calcineurin 
inhibitor reduction/NCT02474199
NIAID 1. University of California 
at San Francisco, USA
September 2015/
December 2018/18/
Phase 1 and phase 2
To examine the safety of one dose of darTreg and 
to see if the Treg allow the recipient of a living donor 
liver transplant to take less or completely stop the 
medications normally taken after receiving an organ 
transplant
2. Mayo Clinic, 
Minnesota, USA
ThRIL: Safety and efficacy study 
of Treg therapy in liver transplant 
patients/NCT02166177
Guys and St 
Thomas’ NHS 
Foundation Trust
King’s College Hospital June 2014/June 
2019/26/phase 1 and 
phase 2
To examine the feasibility, safety and efficacy 
of an autologous Treg product as an adjunct 
immunosuppressive treatment in liver transplantation
TASK: Treg adoptive therapy for 
subclinical inflammation in kidney 
transplantation/NCT02088931
University of 
California, San 
Francisco
University of California, 
San Francisco
March 2014/February 
2016/3
Pilot study of CD4+CD127low/−CD25+ polyclonal Treg 
adoptive immunotherapy in renal transplant recipients. 
The aim is to test the safety of a single infusion of 
autologous expanded Treg
TASK: Treg therapy in subclinical 
inflammation in kidney 
transplantation NCT02711826
NIAD University of California, 
San Francisco
May 2016/April 
2018/45
To see if polyclonal Treg or darTreg can reduce 
inflammation in a transplanted kidney and find out the 
effects of taking everolimus after polyclonal Treg or 
darTreg on the kidney recipient
phase 1 and phase 2 
Autologous polyclonal Treg for 
Lupus/NCT02428309
NIAID University of California, 
San Francisco
July 2015/December 
2019/18/phase 1
To evaluate the safety, tolerability, and effect of 3 
different doses of ex vivo-expanded autologous 
polyclonal Treg therapy in adults with skin (cutaneous) 
involvement of their lupus
NIAID, National Institute of Allergy and infectious Diseases; Treg, regulatory T cell; darTreg, donor alloantigen reactive regulatory T cell.
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markers of activation such as latency-associated peptide (LAP) 
and glycoprotein A repetitions predominant (GARP) might help 
to generate a product with a higher proportion of antigen-specific 
Treg (Figure 4).
Clinical trials of Treg therapy for solid organ transplantation 
and autoimmune diseases that are listed on www.ClinicalTrials.
gov and currently recruiting are summarized in Table 1.
SUMMARY
Overall, Treg hold promise as personalized therapy in the treat-
ment of liver diseases and, in the future, may be applied in the 
non-transplant as well as post-transplant setting to overcome 
or minimize the use of broad spectrum immunosuppressant 
medications that have unfavorable side effects (79). Their 
mechanisms of function vary at different tissues. While Treg 
therapy has been applied in other autoimmune disease set-
tings, such as diabetes and SLE, successful application in the 
treatment of the liver diseases, including autoimmune-related 
liver patients, may require consideration of the impact of the 
inflamed liver microenvironment itself which is enriched with 
cytokines, microbes, and metabolites. Dissecting the clonotype 
and gene signature would facilitate exploration of antigen 
specificity, and therapy can be optimized by administering 
antigen-specific Treg. Notably, it is already clear that the effec-
tive proliferation and function of Treg is dependent on IL-2, 
yet the liver microenvironment is deficient in IL-2 (15). Thus, 
it is anticipated that Treg therapy for liver diseases would 
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benefit from adjuvant supply of low-dose IL-2, which can 
selectively potentiate Treg function without establishing global 
immune activation. It is now an exciting time to conduct Treg 
cell therapy with manipulation of different cytokines and the 
microenvironment to achieve a successful and potential cure in 
patients with AILD.
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